- Home
- PVBC vs MOLN Comparison
PVBC vs MOLN Comparison
Compare PVBC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVBC
- MOLN
- Stock Information
- Founded
- PVBC 1913
- MOLN 2004
- Country
- PVBC United States
- MOLN Switzerland
- Employees
- PVBC N/A
- MOLN N/A
- Industry
- PVBC Major Banks
- MOLN
- Sector
- PVBC Finance
- MOLN
- Exchange
- PVBC Nasdaq
- MOLN Nasdaq
- Market Cap
- PVBC 191.3M
- MOLN 195.4M
- IPO Year
- PVBC 2015
- MOLN 2021
- Fundamental
- Price
- PVBC $10.74
- MOLN $5.81
- Analyst Decision
- PVBC Hold
- MOLN
- Analyst Count
- PVBC 1
- MOLN 0
- Target Price
- PVBC $12.00
- MOLN N/A
- AVG Volume (30 Days)
- PVBC 31.3K
- MOLN 8.2K
- Earning Date
- PVBC 01-23-2025
- MOLN 03-13-2025
- Dividend Yield
- PVBC N/A
- MOLN N/A
- EPS Growth
- PVBC N/A
- MOLN N/A
- EPS
- PVBC 0.32
- MOLN N/A
- Revenue
- PVBC $55,219,000.00
- MOLN $7,105,397.00
- Revenue This Year
- PVBC N/A
- MOLN N/A
- Revenue Next Year
- PVBC $5.90
- MOLN $29.41
- P/E Ratio
- PVBC $34.65
- MOLN N/A
- Revenue Growth
- PVBC N/A
- MOLN N/A
- 52 Week Low
- PVBC $7.36
- MOLN $3.32
- 52 Week High
- PVBC $12.32
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- PVBC 40.42
- MOLN 58.86
- Support Level
- PVBC $10.51
- MOLN $4.98
- Resistance Level
- PVBC $11.33
- MOLN $5.91
- Average True Range (ATR)
- PVBC 0.24
- MOLN 0.26
- MACD
- PVBC -0.06
- MOLN 0.09
- Stochastic Oscillator
- PVBC 19.49
- MOLN 91.39
About PVBC Provident Bancorp Inc. (MD)
Provident Bancorp Inc provides a range of banking products and services to small and medium-sized commercial customers. It attracts deposits from the general public and uses those funds to originate loans, commercial real estate, construction and land, and commercial business loans, and to invest in securities. The company lending activities include providing commercial real estate loans, multi-family residential real estate loans, commercial business loans, construction and land development loans, one-to four-family residential loans, home equity loans & lines of credit, and consumer loans.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.